Association between Sex and Immune-Related Adverse Events during Immune Checkpoint Inhibitor Therapy

Ying Jing, Yongchang Zhang, Jing Wang, Kunyan Li, Xue Chen, Jianfu Heng, Qian Gao, Youqiong Ye, Zhao Zhang, Yaoming Liu, Yanyan Lou, Steven H. Lin, Lixia Diao, Hong Liu, Xiang Chen, Gordon B. Mills, Leng Han

    Research output: Contribution to journalArticlepeer-review

    6 Scopus citations

    Abstract

    Background: Accumulated evidence supports the existence of sex-associated differences in immune systems. Understanding the role of sex in immune-related adverse events (irAEs) is important for management of irAE in patients receiving immunotherapy. Methods: We performed meta-analysis on published clinical study data and multivariable logistic regression on pharmacovigilance data and applied a propensity algorithm to The Cancer Genome Atlas omics data. We further validated our observations in 2 independent in-house cohorts of 179 and 767 cancer patients treated with immune checkpoint inhibitors. Results: A meta-analysis using 13 clinical studies that reported on 1096 female patients (36.8%, 95% confidence interval [CI] = 35.0% to 38.5%) and 1886 male patients (63.2%, 95% CI = 61.5% to 65.0%) demonstrated no statistically significant irAE risk difference between the sexes (odds ratio [OR] = 1.19, 95% CI = 0.91 to 1.54, 2-sided P =. 21). Multivariable logistic regression analysis of 12 225 patients from the Food and drug administration Adverse Event Reporting System (FAERS) and 10 979 patients from VigiBase showed no statistically significant difference in irAEs by sex. A propensity score algorithm used on multi-omics data for 6019 patients from The Cancer Genome Atlas found no statistically significant difference by sex for irAE-related factors or pathways. The retrospective analysis of 2 in-house patient cohorts validated these results (OR = 1.55, 95% CI = 0.98 to 2.47, false discovery rate = 0.13, for cohort 1; OR = 1.16, 95% CI = 0.86 to 1.57, false discovery rate = 0.39, for cohort 2). Conclusions: We observed minimal sex-associated differences in irAEs among cancer patients who received immune checkpoint inhibitor therapy. It may be unnecessary to consider sex effects for irAE management in clinical practice.

    Original languageEnglish (US)
    Pages (from-to)1396-1404
    Number of pages9
    JournalJournal of the National Cancer Institute
    Volume113
    Issue number10
    DOIs
    StatePublished - Oct 1 2021

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint

    Dive into the research topics of 'Association between Sex and Immune-Related Adverse Events during Immune Checkpoint Inhibitor Therapy'. Together they form a unique fingerprint.

    Cite this